Effects of modified Shu-Gan-Liang-Xue decoction combined with anastrozole on osteoblastic proliferation and differentiation of MC3T3-E1 cells

Zhou,Fei; Han,Shuyan; Zhou,Ning; Zheng,Wenxian; Li,Pingping

doi:10.3892/mmr.2014.2962

Effects of modified Shu-Gan-Liang-Xue decoction combined with anastrozole on osteoblastic proliferation and differentiation of MC3T3-E1 cells

Authors:
- Fei Zhou
- Shuyan Han
- Ning Zhou
- Wenxian Zheng
- Pingping Li
View Affiliations

Affiliations: Key Laboratory of Carcinogenesis and Traditional Research (Ministry of Education), Department of Integrated Traditional Chinese and Western Medicine, Peking University Cancer Hospital and Institute, Beijing 100142, P.R. China
Published online on: November 17, 2014 https://doi.org/10.3892/mmr.2014.2962
Pages: 1639-1646
Copyright: © Zhou et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Aromatase inhibitors (AIs) are widely used in the treatment of hormone‑dependent breast cancer and as a result, aromatase inhibitor‑associated bone loss (AIBL) has become a major concern amongst patients receiving AI treatment. Modified Shu‑Gan‑Liang‑Xue decoction (mSGLXD), a clinical prescription, has been used for ameliorating AIBL in patients with breast cancer for decades and has achieved good clinical efficacy. However, the mechanism underlying how mSGLXD influences bone homeostasis and alleviates AIBL has remained elusive. In the present study, mSGLXD was supplemented with Rhizoma Drynariae containing phytoestrogens, and the safety of mSGLXD was evaluated. mSGLXD did not possess estrogenic activity and significantly inhibited the proliferation of estrogen receptor‑positive breast cancer cell line MCF‑7, which suggested that mSGLXD was safe for postmenopausal patients with breast cancer. Subsequently, the effects of mSGLXD alone or in combination with anastrozole on osteoblastic MC3T3‑E1 cell proliferation and differentiation were investigated. Cell counting kit‑8, reverse transcription‑polymerase chain reaction and biochemical methods, such as ELISA and alizarin red S staining, were used in the present study. It was revealed that mSGLXD not only stimulated MC3T3‑E1 cell proliferation, but also upregulated alkaline phosphatase and osteocalcin gene and protein expression levels. High concentrations of anastrozole (10 or 100 µmol/l) markedly inhibited MC3T3‑E1 cell proliferation, but this inhibitory effect was attenuated by mSGLXD. Furthermore, mSGLXD increased MC3T3‑E1 cell mineralization following β‑glycerophosphate and ascorbic acid induction. Therefore, the results of the present study suggested that mSGLXD may be a promising adjuvant therapy, with high safety and efficacy, for the prevention and treatment of AIBL in patients with breast cancer who receive AI treatment.

View Figures

View References

1	Kwong A, Cheung PS, Wong Y, et al: The acceptance and feasibility of breast cancer screening in the East. Breast. 17:42–50. 2008. View Article : Google Scholar
2	Clemons M and Goss P: Estrogen and the risk of breast cancer. N Engl J Med. 344:276–285. 2001. View Article : Google Scholar : PubMed/NCBI
3	Brueggemeier RW, Hackett JC and Diaz-Cruz ES: Aromatase inhibitors in the treatment of breast cancer. Endocr Rev. 26:331–345. 2005. View Article : Google Scholar : PubMed/NCBI
4	Smith IE and Dowsett M: Aromatase inhibitors in breast cancer. N Engl J Med. 348:2431–2442. 2003. View Article : Google Scholar : PubMed/NCBI
5	Geisler J, Haynes B, Anker G, Dowsett M and Lønning PE: Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol. 20:751–757. 2002. View Article : Google Scholar : PubMed/NCBI
6	Geisler J, King N, Anker G, Ornati G, Di Salle E, Lønning PE and Dowsett M: In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res. 4:2089–2093. 1998.PubMed/NCBI
7	Miller WR and Dixon JM: Local endocrine effects of aromatase inhibitors within the breast. J Steroid Biochem Mol Biol. 79:93–102. 2001. View Article : Google Scholar
8	Coombes RC, Hall E, Gibson LJ, et al: Intergroup Exemestane Study: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 350:1081–1092. 2004. View Article : Google Scholar : PubMed/NCBI
9	Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M and Forbes JF: ATAC/LATTE investigators: Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 11:1135–1141. 2010. View Article : Google Scholar : PubMed/NCBI
10	Thürlimann B, Keshaviah A, Coates AS, et al: Breast International Group (BIG) 1–98 Collaborative Group: A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 353:2747–2757. 2005. View Article : Google Scholar
11	Coates AS, Keshaviah A, Thürlimann B, et al: Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1–98. J Clin Oncol. 25:486–492. 2007. View Article : Google Scholar : PubMed/NCBI
12	Nabholtz JM, Bonneterre J, Buzdar A, Robertson JF and Thürlimann B: Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. Eur J Cancer. 39:1684–1689. 2003. View Article : Google Scholar : PubMed/NCBI
13	Perez EA: Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer. Ann Oncol. 18(Suppl 8): viii26–viii35. 2007. View Article : Google Scholar : PubMed/NCBI
14	Ettinger B, Pressman A, Sklarin P, Bauer DC, Cauley JA and Cummings SR: Associations between low levels of serum estradiol, bone density, and fractures among elderly women: the study of osteoporotic fractures. J Clin Endocrinol Metab. 83:2239–2243. 1998.PubMed/NCBI
15	Kenny AM and Raisz LG: Mechanisms of bone remodeling: implications for clinical practice. J Reprod Med. 47(1 Suppl): 63–70. 2002.PubMed/NCBI
16	Ernst M, Schmid C and Froesch ER: Enhanced osteoblast proliferation and collagen gene expression by estradiol. Proc Natl Acad Sci USA. 85:2307–2310. 1988. View Article : Google Scholar : PubMed/NCBI
17	Kameda T, Mano H, Yuasa T, et al: Estrogen inhibits bone resorption by directly inducing apoptosis of the bone-resorbing osteoclasts. J Exp Med. 186:489–495. 1997. View Article : Google Scholar : PubMed/NCBI
18	Pant S and Shapiro CL: Aromatase inhibitor-associated bone loss: clinical considerations. Drugs. 68:2591–2600. 2008. View Article : Google Scholar : PubMed/NCBI
19	McCloskey E: Effects of third-generation aromatase inhibitors on bone. Eur J Cancer. 42:1044–1051. 2006. View Article : Google Scholar : PubMed/NCBI
20	Lester JE, Dodwell D, Purohit OP, et al: Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res. 14:6336–6342. 2008. View Article : Google Scholar : PubMed/NCBI
21	Brufsky AM, Bosserman LD, Caradonna RR, et al: Zoledronic acid effectively prevents aromatase inhibitor–associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer. 9:77–85. 2009. View Article : Google Scholar : PubMed/NCBI
22	Eidtmann H, de Boer R, Bundred N, et al: Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol. 21:2188–2194. 2010. View Article : Google Scholar : PubMed/NCBI
23	Llombart A, Frassoldati A, Paija O, et al: Immediate administration of zoledronic acid reduces aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer: 12-month analysis of the E-ZO-FAST trial. Clin Breast Cancer. 12:40–48. 2012. View Article : Google Scholar
24	Ruggiero SL, Mehrotra B, Rosenberg TJ and Engroff SL: Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg. 62:527–534. 2004. View Article : Google Scholar : PubMed/NCBI
25	Bamias A, Kastritis E, Bamia C, et al: Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol. 23:8580–8587. 2005. View Article : Google Scholar : PubMed/NCBI
26	Lee SH, Chang SS, Lee M, Chan RC and Lee CC: Risk of osteonecrosis in patients taking bisphosphonates for prevention of osteoporosis: a systematic review and meta-analysis. Osteoporos Int. 25:1131–1139. 2014. View Article : Google Scholar
27	Xue D, Sun H and Li PP: Long-term chinese herbs decoction administration for management of hot flashes associated with endocrine therapy in breast cancer patients. Chin J Cancer Res. 23:74–78. 2011. View Article : Google Scholar : PubMed/NCBI
28	Wu CX and Li PP: Anti-tumor effect of Shu-Gan-Liang-Xue decoction combined with tamoxifen on estrogen-dependent breast cancer. Chin J Exp Tradit Med Formulae. 14:31–34. 2008.
29	Zhang Y and Li PP: Evaluation of estrogenic potential of Shu-Gan-Liang-Xue Decoction by dual-luciferase reporter based bioluminescent measurements in vitro. J Ethnopharmacol. 126:345–349. 2009. View Article : Google Scholar : PubMed/NCBI
30	Liu X, Zhang S, Lu X, Zheng S, Li F and Xiong Z: Metabonomic study on the anti-osteoporosis effect of Rhizoma Drynariae and its action mechanism using ultra-performance liquid chromatography-tandem mass spectrometry. J Ethnopharmacol. 139:311–317. 2012. View Article : Google Scholar
31	Wong RW, Rabie B, Bendeus M and Hägg U: The effects of Rhizoma Curculiginis and Rhizoma Drynariae extracts on bones. Chin Med. 2:132007. View Article : Google Scholar : PubMed/NCBI
32	Pang WY, Wang XL, Wong KC, Leung PC, Yao XS and Wong MS: Total flavonoid fraction of Rhizoma Drynaria improves bone properties in ovariectomized mice and exerts estrogen-like activities in rat osteoblast-like (UMR-106) cells. JFood Drug Anal. 20:265–269. 2012.
33	Chang EJ, Lee WJ, Cho SH and Choi SW: Proliferative effects of flavan-3-ols and propelargonidins from rhizomes of Drynaria fortunei on MCF-7 and osteoblastic cells. Arch Pharm Res. 26:620–630. 2003. View Article : Google Scholar : PubMed/NCBI
34	Quarles LD, Yohay DA, Lever LW, Caton R and Wenstrup RJ: Distinct proliferative and differentiated stages of murine MC3T3-E1 cells in culture: An in vitro model of osteoblast development. J Bone Miner Res. 7:683–692. 1992. View Article : Google Scholar : PubMed/NCBI
35	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
36	Kim EJ, Bu SY, Sung MK and Choi MK: Effects of silicon on osteoblast activity and bone mineralization of MC3T3-E1 cells. Biol Trace Elem Res. 152:105–112. 2013. View Article : Google Scholar : PubMed/NCBI
37	Peeters PH, Keinan-Boker L, van der Schouw YT and Grobbee DE: Phytoestrogens and breast cancer risk. Review of the epidemiological evidence. Breast Cancer Res Treat. 77:171–183. 2003. View Article : Google Scholar : PubMed/NCBI
38	Adlercreutz H: Phyto-oestrogens and cancer. Lancet Oncol. 3:364–373. 2002. View Article : Google Scholar : PubMed/NCBI
39	Keinan-Boker L, van Der Schouw YT, Grobbee DE and Peeters PH: Dietary phytoestrogens and breast cancer risk. Am J Clin Nutr. 79:282–288. 2004.PubMed/NCBI
40	Trock BJ, Hilakivi-Clarke L and Clarke R: Meta-analysis of soy intake and breast cancer risk. J Natl Cancer Inst. 98:459–471. 2006. View Article : Google Scholar : PubMed/NCBI
41	Christenson RH: Biochemical markers of bone metabolism: an overview. Clin Biochem. 30:573–593. 1997. View Article : Google Scholar
42	Hlaing TT and Compston JE: Biochemical markers of bone turnover - uses and limitations. Ann Clin Biochem. 51(Pt 2): 189–202. 2014. View Article : Google Scholar : PubMed/NCBI
43	Speirs V, Walton DS, Hall MC and Atkin SL: In vivo and in vitro expression of steroid-converting enzymes in human breast tumours: associations with interleukin-6. Br J Cancer. 81:690–695. 1999. View Article : Google Scholar : PubMed/NCBI
44	Fu XS and Li PP: Shu-Gan-Liang-Xue decoction simultaneously down-regulates expressions of aromatase and steroid sulfatase in estrogen receptor positive breast cancer cells. Chin J Cancer Res. 23:208–213. 2011. View Article : Google Scholar : PubMed/NCBI
45	Seeman E and Delmas PD: Bone quality - the material and structural basis of bone strength and fragility. N Engl J Med. 354:2250–2261. 2006. View Article : Google Scholar : PubMed/NCBI